Australia is punching above its weight in the global pharmaceutical sector, but the risks often outweigh the rewards for investors inclined to take a punt on business models largely misunderstood by the broader market.

A string of blunders in the sector a decade ago alerted fund managers to the risks of investing in an industry where it can take years to generate revenue, and survival hinges on the outcome of clinical trials rather than the laws of demand.